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ing a longitudinal mixed-effects model incorporating coun-
try effect. Patient demographics were explored for associa-
tions with change over time.  Subjects: Two hundred ninety-
one routinely treated, unilateral CI recipients, aged 13–81 
years, from 9 clinics across 4 countries.  Results: Highly sig-
nificant improvements were observed for all outcome mea-
sures ( p < 0.0001). Postimplantation, mean outcome scores 
remained stable beyond 1 year, with notable individual vari-
ability. A significant association for one or more outcomes 
with preimplantation contralateral hearing aid use, tele-
phone use, age at implantation, implantation side, preim-
plantation comorbidities, dizziness, and tinnitus was ob-
served ( p < 0.004).  Conclusions: Longitudinal benefits of CI 
treatment can be measured using clinically standardized self-
assessment tools to provide a holistic view of patient-related 
benefits in routine clinical practice for aggregated data from 
multinational populations. Self-reported outcomes can pro-
vide medical-based evidence regarding CI treatment to sup-
port decision-making by health service providers. 
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 Abstract 
 Objectives: To assess subjectively perceived, real-world ben-
efits longitudinally for unilateral cochlear implant (CI) recipi-
ents in a multinational population treated routinely. To iden-
tify possible predictors of self-reported benefits.  Design: This 
was a prospective, multicenter, repeated-measures study. 
Self-assessment of performance at preimplantation and 
postimplantation at 1, 2, and 3 years using standardized, val-
idated, local language versions of the Speech, Spatial, and 
Qualities of Hearing Scale (SSQ), and the Health Utilities Index 
Mark 3 (HUI3) was performed. Outcomes were analyzed us-
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 Introduction 
 The increasing demand for access to reliable, large-
scale, longitudinal, patient-related outcome data on rou-
tine clinical treatment, both in and out of the field of co-
chlear implants (CI), underlines a growing need for great-
er universal consistency in the monitoring of treatment 
benefits, and the data collection methods that can serve 
as medical evidence for the respective therapies [Gliklich 
and Dreyer, 2010; Haute Autorité de Sauté, 2011; Nation-
al Institute for Health and Clinical Excellence, 2013; US 
Food and Drug Administration, 2013a, b; World Medical 
Association, 2013]. Such clinical evidence allows various 
stakeholders, including potential candidates, treatment 
recipients, health care professionals, market regulators, 
and health policy makers, to make well-informed deci-
sions on their effectiveness, provision, and reimburse-
ment.
 In the last decade, various health technology assess-
ment appraisals of hearing implants have been performed, 
resulting in guidelines for health practices relating to 
their provision in adults and children in the UK, France, 
and the USA [National Institute for Health and Clinical 
Excellence, 2009; Haute Autorité de Santé, 2011; Tufts 
Evidence-Based Practice Centre under contract by the 
Agency for Health Research and Quality, 2011]. In con-
sideration of the available published evidence for the ap-
praisals, the reports call for clinical research publications 
to include greater transparency of the study methods and 
measures used, greater consistency across studies, larger 
treatment cohorts, more detail regarding the cohort de-
mographics, longer-term follow-up, treatment controls, 
and appropriate outcome measures that also reflect pa-
tient-related benefits in the real world [National Institute 
for Health and Clinical Excellence, 2009; Tufts Evidence-
Based Practice Centre under contract by the Agency for 
Health Research and Quality, 2011].
 The use of multicenter patient registries on a national 
level has the potential to yield large amounts of data and 
to improve the efficiency of the data collection process; 
however, it is acknowledged that there are challenges as-
sociated with the high costs of the initial setup and main-
tenance and the need for adaptation of clinical practices 
in order for them to be adopted [Berrettini et al., 2011]. 
Successful examples of nationally based registries to cap-
ture CI patient outcomes, based on standard audiological 
measures, have been implemented and sustained in the 
long term both in France and Switzerland, involving all 
implanting CI clinics, all commercially available CIs, and 
recipients of all ages [Merrina, unpubl. data; Brand et al., 
2014]. With the number of enrolled CI recipients exceed-
ing several thousands, they provide credible evidence of 
the safety and clinical effectiveness of CI treatment in 
routine care. Nonetheless, there is little or no insight into 
patient-related benefits in the real world.
 In September 2011, the Cochlear Implant Recipient 
Observational Study (IROS), an international, voluntary, 
observational study of the patient-related benefits ob-
tained in routine therapy, was initiated by Cochlear LTD 
(Sydney, NSW, Australia). Implemented via an electron-
ic platform to facilitate consistent data collection, the on-
going study includes 2 main outcome measures: the 
Speech, Spatial, and Qualities of Hearing Scale (SSQ), an 
established disease-specific measure of daily hearing 
function, and the Health Utilities Index Mark 3 (HUI3), 
a widely used, generic measure of health utility gains 
[Feeny et al., 1995; Noble and Gatehouse, 2004].
 The aim of this study was to determine real-life treat-
ment benefits among unilateral CI treatment recipients 
from a multinational cohort in routine care, via repeated 
measures of the HUI3 and the SSQ. Furthermore, the as-
sessment of recipient variables as potential predictors of 
change in outcomes over time was undertaken.
 To our knowledge, this is the first report of a collab-
orative, international effort to collect, aggregate, and de-
scribe longitudinal self-reported patient-related benefits 
for unilateral CI recipients in routine care.
 Methods 
 This prospective observational study had a repeated measures 
design and was conducted in accordance with the Declaration of 
Helsinki (ethical principles for medical research involving human 
subjects) and international guidelines for the conduction and re-
porting of clinical investigations [International Organization for 
Standardization, 2011; World Medical Association, 2013]. Ethics 
committee approval for study participation was obtained for each 
participating clinic as required at the national or local level. The 
outline of the Cochlear IROS and the list of approving ethics
committees are available for public access (ClinicalTrials 
#NCT2004353, https://clinicaltrials.gov).
 Formal written informed consent was obtained from each re-
cipient prior to their enrolment into this study. Clinics were ad-
vised to approach patients in chronological order, following their 
decision to implant any hearing device from the company Cochle-
ar Ltd., for consent to participate in the study. Patients were ap-
proached between the day of surgery and the first switch-on of 
their external sound processor. In the case of adolescents (age 10–
17 years), their carer was approached for consent.
 Participating Sites 
 For inclusion in this study, clinics participating in the study for 
 ≥ 2 years that had enrolled  ≥ 10 CI recipients with longitudinal data 
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at the time of data extraction (October 2015) were approached to 
share their data for collective analysis. All 9 implant centers ap-
proached agreed to participate. This included 1 German, 1 South 
African, 3 Spanish, and 4 Polish clinics. All available data for the 
respective 291 enrolled unilateral CI recipients were included in 
the analysis ( Fig. 1 ).
 Main Outcome Measures 
 Health Utilities Index 3: The “4-week recall” version of the self-
assessed HUI3 with 15 questions was completed at each assess-
ment interval. Licensed versions in English, Spanish, German, and 
Polish were obtained from the developers, Health Utilities Inc., 
while an Afrikaans language version was developed for this study 
and shared with the developers. In this generic health-related qual-
ity of life questionnaire, the responder is asked to assess their per-
ceived degree of impairment in each of 8 subdomains of health: 
vision, hearing, speech, ambulation, dexterity, emotion, cognition, 
and pain [Feeny et al., 1995, 2002]. A multiattribute health utility 
score is derived that enables classification of the respondent’s over-
all health status into predefined health states ranging from –0.36 
to 1.00, where a negative score represents a state “worse than dead” 
and a top score of 1.00 is perfect health. A significant change in 
health utility gain between assessment intervals of 0.03 was used 
[Feeny et al., 2002]. The HUI3 was selected over other global health 
utility measures available as it is considered to be the most sensitive 
measure for effects of hearing treatment on overall health status 
[UK Cochlear Implant Study Group, 2004; Damen et al., 2007; 
Maes et al., 2011].
 The Speech, Spatial, and Qualities of Hearing Scale: The SSQ 
with 49 questions divided into 3 subcategories was used for self-
assessment of hearing function at each interval. The SSQ is a stan-
dardized, hearing disease-specific questionnaire in which the re-
sponder is asked to assess their hearing ability with reference to a 
variety of realistic, real-world listening situations [Gatehouse and 
Noble, 2004]. The SSQ was chosen as it has been reported to be 
sensitive to changes in hearing function following treatment with 
a variety of hearing therapies, implantable and nonimplantable 
hearing devices, and stimulation configurations [Noble and Gate-
house, 2006; Noble et al., 2008; Laske et al., 2009; House et al., 2010; 
Noble, 2010; Pai et al., 2012; Mertens et al., 2015]. While many ver-
sions of the SSQ exist, the English version 5.6 with 49 questions, 
available online from the British Medical Research Council, was 
used as a master version for subsequent validated translations to 
German, Spanish, Polish, and Afrikaans.
 Each question was scored on a 21-point rating scale ranging 
from 0 to 10, corresponding to minimum and maximum hearing 
abilities, respectively. Subsequently, subcategory mean scores were 
derived by averaging responses across all questions within each 
category. Clinically significant changes in subcategory scores be-
tween assessments were set at  ≥ 1.0 [Noble and Gatehouse, 2006].
 Translations for Evaluation Tools 
 All case report forms and outcome measures completed by the 
implant recipient were provided in their native language. Clinician 
questionnaires were also provided in the local native language and 
in English for clinicians in South Africa. While the case report 
forms used to gather hearing profile and demographic information 
followed a 1-way translation process of the English master version 
to each respective language, both main outcome scales, i.e., HUI3 
and SSQ, were translated via the recommended validated transla-
tion process by the respective scale developers.
 The process of validation of the translation of SSQ version 5.6 
(available through the British Medical Research Council) was a 
forward and backward validation translation process involving 
professional certified translators and proofers. In brief: the SSQ 
was translated from English to the required native language by 
translator 1; the new native-language version was then translated 
backward to English by translator 2; an English proofer then com-
pared the English backward-translated version to the original En-
glish master version, identifying and annotating discrepant context 
or content for further address. Annotations were addressed and 
incorporated by translator 1 to finalize the new language version.
 The process of validation of the translation for the HUI3 4-week 
recall version was documented and controlled by the licensers and 
developers of the HUI3 (HUI Inc.). In summary, this involved a 
validation translation process requiring 2 forward-translation ver-
sions from English to the new language by translator 1 and transla-
tor 2 in parallel. A third proofer/translator decided on the best 
Implant recipients (all devices) registered in the Cochlear IROS
(14 countries, 30 clinics):
n = 578
CI patients:
n = 297
Unilateral-CI patients:
n = 291
(analysis group)
Bilateral-CI patients:
n = 6
Implanted recipients (all devices) registered in 9 author clinics:
n = 352
Baha patients:
n = 14
Acoustic-implant patients:
n = 37
Multiple-device patients:
n = 4
 Fig. 1. Global registration of hearing im-
plant recipients with all device types and 
configurations as enrolled across 30 partic-
ipating implant sites and the subset of 291 
unilateral cochlear implant (CI) recipients 
included in this study enrolled at the 9 co-
author clinics (data extraction date: Octo-
ber 30, 2015). 
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version per question/phrase and compiled the final validated 
translation version. (Note: to enable recipients to respond in their 
native language for self-assessment, validated translations were 
implemented for: Afrikaans, Arabic, Danish, Dutch, English, 
French, German, Hebrew, Hungarian, Japanese, Polish, Portu-
guese [Brazilian and European versions], Slovenian, Spanish, 
Swedish, and Turkish.)
 Evaluation Schedule 
 The evaluation intervals for baseline (preimplantation status) 
and postimplantation at 1, 2, and 3 years were adopted to coincide 
with routine annual clinical follow-up visits (i.e., ±2 months at 
each expected annual visit date). Preimplantation assessment was 
performed following the decision of implant treatment and device 
type and configuration between the day of surgery and before the 
first switch-on of the sound processor. This was to avoid the influ-
ence of the new hearing sensation via the hearing implant system 
for baseline self-assessment of the preimplantation hearing and 
health status. At each assessment interval, a 4-week recall period 
was referenced, i.e., “4 weeks prior to implant surgery” for baseline 
and “within the last 4 weeks” at each postimplantation interval.
 HUI3 and SSQ self-assessments were completed by the recipi-
ent either on paper (usually in the clinic or at home) or directly 
online depending their choice upon consent to participate. Data 
entry was performed from the completed paper forms by a repre-
sentative of the clinic. By study design, and through the use of au-
toprompts for online data entry, 100% completion of the HUI3 
and at least 45 out of 49 questions for the SSQ were requested as 
required for analysis.
 Subject Inclusion 
 Any routinely treated hearing-impaired adult or adolescent 
(>10 years old), meeting local criteria for hearing implant treat-
ment with any hearing implant from the company Cochlear was 
eligible for enrolment ( Fig. 1 ). Only data for enrolled unilateral CI 
recipients were included in this study. At online enrolment, a sub-
ject study code was automatically assigned to each recipient, thus 
maintaining their full anonymity on the study platform. Patient 
demographics including medical and hearing histories were col-
lected both via the clinician from the patient hospital file and via 
the recipient directly at enrolment using the respective case report 
forms ( Table 1 ). However, responses to individual demographic 
questions on these case report forms were not compulsory, thus 
allowing for missing responses.
Gender
Female 163 (56)
Male 128 (44)
Age at implantation
<18 years 6 (2)
18 – 64 years 223 (77)
65+ years 62 (21)
Progression/onset
Progressive 196 (67)
Sudden 75 (26)
NA 20 (7)
Hearing loss type
Mixed/other 9 (3)
Sensorineural 169 (58)
NA 113 (39)
Preimplantation HA
Bilateral 115 (40)
Unilateral, either ear 60 (21)
Unaided 103 (35)
NA 13 (4)
Employment
Full time 124 (43)
Part time 16 (5)
Retired 76 (26)
Unemployed 57 (20)
NA 18 (6)
Duration of HL
Mean ± SD: 22.6 ± 15.4 years 256 (88)
NA 35 (12)
Implant ear
Left 127 (44)
Right 164 (56)
Hearing loss degree
Moderate-severe 33 (11)
Profound 153 (53)
NA 105 (36)
Tinnitus
No 102 (35)
Yes 151 (52)
NA 38 (13)
Comorbidities
No 253 (87)
Yes 22 (8)
NA 16 (5)
Dizziness
Never 124 (43)
Sometimes 99 (34)
Half the time or more 30 (10)
NA 38 (13)
Telephone use
Yes 143 (49)
No 130 (45)
NA 18 (6)
Country
Germany 56 (19)
Poland 98 (34)
South Africa 87 (30)
Spain 50 (17)
Table 1.  Demographics of the 291 enrolled unilaterally implanted cochlear implant recipients
Values are presented as n (%).  NA, not available/not answered; HA, hearing aid; HL, hearing loss.
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 Statistical Analysis 
 The aim of the data analysis reported in this paper is to address 
the following questions:
 1. How do outcomes for HUI3 and SSQ scores change over 
time for the unilateral CI cohort?
 2. What is the nature of the missing data at follow-up inter-
vals and the impact on outcomes?
 3. Are preimplantation patient variables associated with 
longitudinal outcomes for SSQ and HUI3?
 Analysis of all of the available data extracted from the central 
database, the Cochlear IROS, on October 30, 2015, was undertak-
en using R version 3.2.0 [R Core Team, 2015]. Statistical analysis 
was performed by a coauthor (consultant statistician at Macquarie 
University, Sydney, Australia).
 For description of the data, a summary of continuous variables 
using means and SD or SE and of categorical variables using num-
bers per subgroup and percentage of the total study cohort was 
created.
 Examination of the missing outcome data and their impact on 
cohort outcomes was undertaken to explore the potential for in-
formative missing status. Outcomes for recipients with subsequent 
missing follow-up data were compared to outcomes for recipients 
with no missing data. In this context, informative missing status 
would result if the reason for dropout were related to hearing per-
formance as opposed to random dropout that might occur due to 
work, vacation, or non-hearing-related illness. The mean out-
comes for subgroups with missing data and no missing data were 
compared using Welch 2-sample  t tests to determine whether sys-
tematic differences between the subgroups existed that might sug-
gest evidence of nonrandom missing status.
 Linear mixed-effects models were used to model changes over 
time with a nested random intercept for recipient within country 
to control for the correlation induced through repeated measures 
on the same recipients and to control for country effects. Tukey 
pairwise differences were used to compare all pairs of time points. 
Linear mixed-effects models provide unbiased estimates of effects 
in the presence of randomly missing responses [Little and Rubin, 
2002].
 To determine whether multicultural subgroups differed in 
their response on HUI3 and SSQ subcategories, the variable coun-
try was initially incorporated as a predictor into the linear mixed-
effects model with a random intercept for recipient using an inter-
action between country and assessment time point. A random in-
tercept for country (with recipient nested within country) was then 
incorporated into the model to control for significant country-
time interactions.
 Interactions between time of assessment and 12 recipient vari-
ables collected at baseline were examined for their association with 
HUI3 and SSQ subcategory scores. If the interaction with time was 
not significant, the main effects were examined. A Bonferroni type 
correction to the significance level was used to control for the 12 
recipient variables assessed for each outcome measure. As such, an 
interaction or main effect was considered significant for a modi-
fied  p value <0.004 (0.05/12). For significant interactions in cate-
gorical variables with more than 2 groups, Tukey’s pairwise mul-
tiple comparisons were used to determine which groups differed 
at which time points. Postimplantation variables were not ex-
plored for their impact on outcomes for this study.
 Results 
 Enrolled Implant Population 
 At the time of data extraction, a total of 578 implant 
recipients with a variety of hearing implants had been en-
rolled by more than 30 international collaborating clinics. 
The 9 coauthor implant clinics enrolled 352 recipients, 
297 of whom were CI recipients (291 unilateral implant-
ees and 6 sequential bilateral CI users) ( Fig. 1 ).
 Study Cohort Demographics 
 Table 1 illustrates the summary demographics for the 
study cohort of 291 unilateral CI recipients. The national 
contributions of the recipients were as follows: about one 
third were from Poland and South Africa and about one 
fifth were from Germany and Spain. The cohort com-
prised slightly more female than male recipients. The 
mean age of the cohort was 50.1 years (SD 17.4, range 
13–91), the majority (i.e., about four fifths) were aged 18–
64 years, about one fifth of the subjects were aged  ≥ 65 
years at implantation, and 6 were of adolescent age (range 
13–17 years). The duration of hearing loss, reported for 
88% of the cohort, was 22.6 years on average (SD 15.4, 
range 0–67), while no response was provided by 12 re-
cipients.
 Approximately half of the recipients presented with 
right-sided implants, and more than two thirds had a pro-
gressive onset of hearing loss. Hearing loss degree and 
type of hearing loss in the implant ear, reported for two 
thirds of the cohort, were sensorineural and of a profound 
degree for the vast majority.
 Prior to implantation, approximately equal sized sub-
groups reported experiencing dizziness versus never ex-
periencing it (i.e., 44 and 43%, respectively), while 13% 
did not respond. Tinnitus was experienced by about half 
of the subjects and it was never experienced by about one 
third of the subjects, while 13% of the cohort did not re-
spond. Comorbidities were absent in the vast majority of 
patients (i.e., 87%) and present in 8% of the cohort; no 
response was provided for 5% of the group.
 Preimplantation acoustic amplification was used by 
61% of the cohort in either a bilateral (40%) or a unilat-
eral (21%) configuration. More than one third (35%) of 
the subjects reported that they did not use amplification 
immediately prior to implant surgery, while no response 
was available for 4% of the patients. Not shown in  Ta-
ble 1 , the daily hearing aid use on the implant side ( n = 
174) averaged 13.7 h (SD 4.3) and 13.9 h (SD 4.1) for the 
contralateral ear ( n = 174), ranging between 0 and 24 h 
for each ear. Approximately equal subgroups reported 
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that they could or could not use the telephone (i.e., 49 
and 45%, respectively), and 6% did not respond. Active 
employment was reported by about half of the recipi-
ents; about one fourth of the subjects were retired, about 
one fifth were unemployed, and 6 recipients did not re-
ply.
 Not shown in  Table 1 , the most frequently reported 
etiology for the implant ear was unknown etiology ( n = 
109; 37%), followed by familial ( n = 22; 8%), otosclerosis 
( n = 15; 5%), meningitis ( n = 12; 4%), ototoxic drugs ( n = 
11; 4%), and noise exposure ( n = 11; 4%). Many other eti-
ologies made up the remaining 38%. Etiology was not 
considered for further analysis.
 Postimplantation, all enrolled unilateral CI recipients 
were implanted with Nucleus ® CI (Cochlear LTD), in-
cluding the Nucleus ® Freedom CI24RE (CA) and the Nu-
cleus ® CI422 for the vast majority, followed by the Nu-
cleus ® CI512. Four patients were implanted each with the 
Nucleus ® 24 Contour Advance ® and with the Nucleus ® 
Hybrid-CI24REH. Implant model was not considered for 
further analysis. At the time of data extraction, the time 
since surgery was on average 2.6 years (SD 1.1, range 0.2–
4.9).
 At 1 year postimplantation, the majority of the unilat-
eral CI recipient study cohort (i.e., 91%; 183/201) present-
ed as all-day implant users, with a mean daily use of 14.1 
h (SD 3.3, range 3–24). In addition, contralateral hearing 
aid use was reported by 50% of the cohort (100/201).
 Baseline Performance Outcome Data 
 The mean SSQ and HUI3 outcomes for the group at 
baseline for the preimplantation condition are shown in 
 Table 2 , along with the SE. HUI3 multiattribute health 
utility values ranged from –0.197 to 1.00 for the individ-
ual, with a cohort mean of 0.46. SSQ subcategory cohort 
mean scores ranged from 2.2 to 3.4, and those for the in-
dividual ranged from 0 to 10.
 Baseline mean scores for enrolled unilateral CI recipi-
ents with missing 1-year follow-up data at the time of data 
extraction (27% of recipients) with mean scores for re-
cipients who had 1-year postimplantation follow-up data 
are compared and shown in  Table 3 . Two-sample  t tests 
 Table 2.  Estimated SSQ and HUI3 outcomes at each visit with p value for the overall test of a change between one or more pairs of eval-
uation time points
Outcome n Baseline 1 year 
postimplantation
2 years 
postimplantation
3 years 
postimplantation
p value
HUI3 multiattribute 282 0.457 (0.015) 0.606 (0.018) 0.600 (0.022) 0.540 (0.038) <0.001
SSQ speech 276 2.197 (0.201) 4.553 (0.212) 4.597 (0.236) 5.006 (0.338) <0.001
SSQ spatial 276 2.357 (0.125) 4.616 (0.144) 4.616 (0.180) 4.883 (0.306) <0.001
SSQ qualities 274 3.380 (0.210) 5.508 (0.221) 5.600 (0.249) 6.311 (0.359) <0.001
Values are presented as means (SE) unless otherwise stated. SSQ, Speech, Spatial, and Qualities of Hearing Scale; HUI3, Health Util-
ities Index Mark 3.
 Table 3.  Baseline data for all registered unilateral cochlear implant recipients for HUI3 and SSQ subcategories with missing and not 
missing follow-up data and p values from Welch 2-sample t tests
Not missing at 1 year postimplantation Missing at 1 year post implantation p value
n mean (SD) n m ean (SD)
HUI3 multiattribute 201 0.453 (0.244) 81 0.469 (0.279) 0.647
SSQ speech 195 2.175 (1.787) 81 2.249 (2.010) 0.774
SSQ spatial 195 2.411 (1.974) 81 2.237 (1.956) 0.503
SSQ qualities 194 2.311 (2.148) 80 3.380 (2.397) 0.922
SSQ, Speech, Spatial, and Qualities of Hearing Scale; HUI3, Health Utilities Index Mark 3.
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 suggest no evidence of a difference between mean out-
come responses for the subgroup with missing data ver-
sus the subgroup with no missing data for all measures
( p > 0.50). Similar results were seen when comparing data 
at 1-year postimplantation for the subgroup with missing 
data versus the subgroup with no missing data at the sec-
ond year postimplantation and the third year postim-
plantation ( p > 0.07, results not presented). Hence, there 
is no evidence of a systematic difference between out-
comes for subjects with missing data and those with no 
missing data at subsequent follow-up intervals. As such, 
the assumption is that, at the time of the data extraction, 
the missing data were missing at random for non-hear-
ing-related reasons.
 The interaction between visit and country upon out-
comes was observed to be significant for the SSQ subcat-
egories speech ( p = 0.022), spatial ( p = 0.002) and qualities 
( p < 0.001), indicating that the effect of country should be 
controlled for in the remaining analyses. In contrast, no 
statistically significant country effect was observed for the 
HUI3 multiattribute score either as an interaction with 
time ( p = 0.433) or as a main effect ( p = 0.050).
 Longitudinal Performance Outcomes 
 The distribution of outcome scores for the available 
data at each time point for each outcome measure is pre-
sented in  Figure 2 . Median scores suggest an increase 
from baseline and stability from 1-year postimplantation 
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 Fig. 2. Box-and-whisker plots showing the distribution of self-as-
sessment outcome scores for Speech, Spatial, and Qualities of 
Hearing Scale (SSQ) subcategories speech ( a ), spatial ( b ), and 
qualities ( c ) and for Health Utilities Index Mark 3 (HUI3) multiat-
tribute utility ( d ). All available data sets at each assessment interval 
are shown for the 291 subjects enrolled in the unilateral cochlear 
implant recipient cohort. Test intervals represent: baseline (preim-
plantation), i.e., 0, and annual follow-up at 1, 2, and 3 years post-
implantation. 
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onwards. At each time point a wide range of scores were 
observed. Estimated mean outcome scores and SE are 
shown for each outcome measure at each assessment in-
terval in  Table 2 . Analysis of change over time suggests a 
highly statistically significant difference in group scores 
between at least one pair of assessments for all outcome 
measures ( p < 0.001).
 Tukey pairwise tests ( Table  4 ) indicated highly sig-
nificant improvements from the baseline interval (i.e., 
preimplantation status) to the first and second year post-
implantation, respectively, for the HUI3 multiattribute
utility scores. Results were similar for the SSQ sub category 
scores, with a significant improvement also observed be-
tween baseline and the third year postimplantation for 
the group ( p < 0.001). No significant differences were ob-
served between other pairs of time points of evaluation
( p > 0.057).
 Predictors of Longitudinal Outcomes 
 The resulting  p values for the univariate analysis of the 
12 preimplantation recipient variables ( Table  1 ) with 
each outcome measure are presented in  Table 5 . Using 
the Bonferroni correction significance level, a significant 
impact upon outcomes was evident for 7 of the 12 vari-
ables examined ( p  ≤ 0.004).
 Recipients with comorbidities had significantly lower 
HUI3 scores than those without reported comorbidities 
(main effect,  p < 0.001). Similarly, those reporting dizzi-
ness or tinnitus prior to implantation had significantly 
lower HUI3 scores compared to those without either con-
 Table 4.  Pairwise comparisons showing difference scores between visits for cochlear implant recipients
Postimplantation 
change
SSQ speech SSQ spatial SSQ qualities  HUI3 multiattribute
change SE p value change SE p value change SE p value c hange SE p value
1 year – BSL 2.356 0.139 0.000* 2.258 0.143 0.000* 2.128 0.150 0.000* 0.149 0.018 0.000*
2 year – BSL 2.400 0.175 0.000* 2.258 0.180 0.000* 2.220 0.189 0.000* 0.143 0.022 0.000*
3 year – BSL 2.809 0.297 0.000* 2.526 0.306 0.000* 2.931 0.320 0.000* 0.082 0.038 0.118
2 year – 1 year 0.044 0.180 0.994 0.000 0.185 1.000 0.091 0.194 0.963 –0.006 0.023 0.993
3 year – 1 year 0.453 0.300 0.416 0.268 0.309 0.813 0.802 0.323 0.057 –0.067 0.038 0.283
3 year – 2 year 0.409 0.309 0.532 0.267 0.317 0.826 0.711 0.333 0.132 –0.060 0.039 0.400
BSL, baseline. * p < 0.05.
 Table 5.  Significance of the interaction between predictor and visit and main effect of the predictor (Bonferroni type correction for mul-
tiple analyses)
Covariate HUI3 multiattribute SSQ speech SSQ spatial  SSQ qualities
inter-
action
main
effect
inter-
action
main
effect
inter-
action
main
effect
inter-
a ction
main
effect
Comorbidities 0.630 <0.001 0.487 0.475 0.412 0.244 0.402 0.905
Gender 0.061 0.684 0.665 0.162 0.630 0.746 0.544 0.390
Age group (<65 vs. 65+ years) 0.027 0.367 0.707 0.004 0.753 0.236 0.132 0.351
Hearing loss degree 0.925 0.650 0.545 0.663 0.021 0.211 0.042 0.730
Implant side 0.141 0.832 0.002 0.098 0.586 0.884 0.336 0.777
Onset of deafness 0.755 0.732 0.338 0.047 0.017 0.058 0.263 0.022
Duration of deafness 0.124 0.963 0.601 0.077 0.818 0.427 0.535 0.062
Telephone use Pre <0.001 <0.001 0.302 <0.001 0.004 <0.001 <0.001 <0.001
Contralateral HA Pre <0.001 0.901 0.131 0.154 0.006 0.687 <0.001 0.901
Employment Pre 0.590 0.008 0.202 0.012 0.995 0.031 0.902 0.009
Tinnitus Pre 0.132 0.001 0.042 0.002 0.066 0.012 0.225 0.001
Dizziness Pre 0.367 <0.001 0.342 0.210 0.280 0.334 0.188 0.319
 Significant p values are in bold. p < 0.004 (0.05/12) was considered statistically significant. Pre, preimplantation; HA, hearing aid.
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dition (main effects,  p < 0.001). Recipients with preim-
plantation tinnitus had significantly lower mean SSQ 
speech and qualities scores (main effects,  p = 0.002 and
 p = 0.001, respectively). A younger age at implantation 
(i.e., <65 years) resulted in significantly higher SSQ speech 
scores than for those aged  ≥ 65 years at implantation ( p = 
0.004).
 A significant interaction was shown between preim-
plantation contralateral hearing aid use and time for both 
the HUI3 multiattribute utility and SSQ qualities scores. 
Pairwise tests indicated that mean scores for both mea-
sures were significantly lower ( p = 0.003 and  p = 0.004, 
respectively) at baseline for recipients who did not wear 
a contralateral hearing aid than for those who did. Con-
versely, at 2 and 3 years postimplantation follow-up, 
mean HUI3 multiattribute utility scores were significant-
ly higher for recipients who did not wear a contralateral 
hearing aid at preimplantation compared to those who 
did ( p = 0.010 and  p = 0.032, respectively). Similarly, at 1 
year postimplantation, SSQ qualities scores were signifi-
cantly higher for recipients who did not use a contralat-
eral hearing aid at preimplantation ( p = 0.009).
 A significant interaction between implant side and 
time for SSQ speech scores was observed ( p < 0.002). 
While no difference was evident at baseline for SSQ 
speech ratings ( p = 0.663), right-sided implantees scored 
significantly higher than left-sided implantes at each an-
nual follow-up interval ( p < 0.031). Telephone use had a 
significant association with all outcome measures at one 
or more time points. After adjusting for time, those who 
used the telephone had significantly higher mean SSQ 
speech scores, than those who did not ( p < 0.001). For 
HUI3 outcomes, a difference was observed only at preim-
plantation, whereby those who used the telephone had 
significantly higher scores ( p < 0.001) than nonusers. No 
impact of preimplantation telephone use was noted on 
HUI3 outcomes at other time points ( p > 0.201). Simi-
larly, for SSQ spatial and qualities scores, at preimplanta-
tion and at 1 year postimplantation assessment intervals, 
those who used the telephone at preimplantation had sig-
nificantly higher scores ( p < 0.032), while there was no 
significant impact thereafter ( p > 0.102).
 Discussion 
 The data presented in this study demonstrate the re-
sults of using the HUI3 and SSQ for longitudinal subjec-
tive assessment of hearing treatment outcomes in routine 
clinical practice in a multinational, multilingual, unilat-
eral, primarily adult, CI recipient cohort. Longitudinal 
analysis demonstrated clinically and statistically highly 
significant patient-related benefits following unilateral 
CI treatment for both health-related quality of life and 
daily hearing ability for the study cohort via the HUI3 and 
the SSQ ( p < 0.0001). Group means remained stable from 
1 year postimplantation to 2 and 3 years postimplantation 
for all outcome measures. This is consistent with the re-
ported daily CI use averaging  ∼ 15 h/day at 2 years post-
implantation, with no report of <7 h per day observed.
 Impact of Missing Data 
 Among the 291 enrolled unilateral CI recipients, 33% 
of the subjects had missing data at one or more follow-up 
time points at the time of extraction. While there are no 
universally agreed upon criteria for acceptable follow-up 
rates in observational cohort studies, rates as high as 80% 
and as low as 60% (i.e., attrition rates between 20 and 
40%) have been suggested in the literature [Kristman et 
al., 2004]. There was no evidence of a statistically signifi-
cant difference between outcomes for those with missing 
data at one or more follow-up time points compared to 
those with no missing data, suggesting that the missing 
data may be randomly missing. Upon closer examination 
of the reasons for the missing observations in our study, 
10 out of 291 recipients were formally withdrawn early 
from this study by the enrolling clinic. The reasons pro-
vided included: death ( n = 2), severe illness (non-hearing 
related) ( n = 3), inability to complete forms reliably due 
to mental incapacity ( n = 2), and reportedly being too 
busy to participate in follow-up appointments ( n = 3). As 
an ongoing observational study, at the time of data extrac-
tion, the time since surgery ranged from just over 2 
months to almost 5 years for the unilateral CI recipient 
cohort. Enrolled recipients with missing follow-up data 
 ≥ 18 months after their surgery date were deemed as lost 
to follow-up ( n = 37), while data entry was considered still 
likely for enrolled recipients with <18 months of CI expe-
rience ( n = 49). This is based on the observation that on-
line data entry at follow-up intervals was delayed by up to 
several months after completion of the clinical assess-
ment in some cases in view of the clinical time constraints 
for performance of the online data entry. Hence the miss-
ing data indicates that the actual subject attrition rate for 
our study could be as high as 33% or as low as 17%. 
 Cohort 
 The study cohort characteristics are similar to those 
reported in the literature for adult unilateral CI recipients 
(only a handful of adolescents were enrolled, consistent 
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with infrequent implantation in new recipients at that 
age). Implanted adult CI groups are often in their early 
50s on average, with a wide age range, a mean duration of 
deafness of close to 2 decades, bilateral deafness with a 
severe to profound degree of loss at minimum and most 
often a profound hearing loss, and presentation of a wide 
range of etiologies, with the most common reported as 
unknown by researchers [UK Cochlear Implant Study 
Group, 2004 ;  Damen et al., 2007; Maes et al., 2011].
 Country Effect 
 The collation of multicenter, multinational data sets 
for group analysis represents outcomes for a variety of 
clinical infrastructures and socioeconomic and cultural 
settings in which hearing treatment with a CI is provided. 
Analysis of the effect of country of origin on the data sets 
did not show an effect on outcomes for the HUI3 multi-
attribute utility scores over time, although the main effect 
was in fact borderline nonsignificant. Researchers who 
compared outcomes from a validated Spanish translation 
version of the HUI3 to the English version (i.e., 15 ques-
tions with a 4-week recall) within a national cross-sec-
tional population sample, with differing ethnicity, social, 
and living conditions, reported that they observed a sig-
nificant cultural effect [Lou et al., 2009]. They hypothe-
sized that the level of optimism, confidence, and willing-
ness to report on health issues may be ethnicity specific 
and, thus, impact the overall health status report.
 Our study confirmed a significant country effect for 
SSQ subcategory scores ( p < 0.02), which resulted in in-
corporation of a random intercept for the variable coun-
try into the subsequent analysis of SSQ scores to control 
for these country-specific differences. This finding is con-
sistent with that reported by researchers developing and 
assessing the validated translation of the SSQ French ver-
sion, following comparison of their data gathered on
normal-hearing and hearing-impaired (nonimplanted) 
French individuals, to published mean data derived from 
hearing-impaired Dutch and English populations [Mou-
lin et al., 2015]. They concluded by recommending that 
the SSQ is considered a feasible international standard 
assessment for use clinically.
 Based on our study findings, our recommendation is 
to assess for country effects when examining aggregated 
multicultural cohort data for SSQ and HUI3 outcomes to 
ensure accountability of significant effects via a mixed-
effects model for further analysis as needed. Furthermore, 
further examination of additional recipient characteris-
tics, such as educational level, social activity, living status 
and ethnicity, may also be beneficial to collate for subse-
quent analysis of their association with outcomes on 
HUI3 and SSQ subjective measures.
 Longitudinal HUI3 Outcomes 
 Our study suggests that the HUI3 is a sensitive mea-
sure of the changes in overall health following hearing 
treatment over time for CI users cross-culturally. Fur-
thermore, as it is a quick and easy self-administered tool 
to use, it is feasible to consider, as part of routine clinical 
assessment, for systematic evaluation of the broader pa-
tient-related benefits of hearing implant treatment.
 Individual analysis suggests that clinically significant 
improvements from baseline were observed by about two 
thirds of the recipient group, which remained stable at 1, 
2, and 3 years postimplantation, while 25% (8/32) of the 
individuals with 3-year data showed a decline in HUI3 
scores from baseline. Upon examination, no differences 
in characteristics were evident between recipients who 
showed a decline and those who remained stable. Both 
subgroups were primarily under 65 years of age, em-
ployed, and without reported comorbidities.
 Also of interest is the subgroup of 6 individuals who 
reported a state “worse than dead” at the 1-year follow-up; 
1 out of 6 patients also reported the negative state at base-
line, while no such reports were observed at the most re-
cent follow-up at 2 years postimplantation ( Fig. 2 d). All 6 
recipients were female, had a mean age of 55.5 years (SD 
11.9, range 35–70), four reported severe pain via the HUI3 
at the 1-year follow-up while the remaining two reported 
poor to severe impairment on at least 2 other domains. 
While the group is too small to make a firm conclusion, 
poor ratings on one or more health domains have the po-
tential to negatively influence the overall HUI3 multiat-
tribute health utility score for the individual.
 Predictors of HUI3 Outcomes 
 For our study cohort differences observed for HUI3 
outcomes were associated with preimplantation report of 
comorbidities, dizziness, tinnitus, telephone use, and 
contralateral hearing aid use. Using the stringent signifi-
cance level of  p = 0.004, we found no association between 
age at implantation or duration of hearing loss and HUI3 
outcomes. The absence of an age effect on HUI3 out-
comes was also reported by researchers from a multi-
center, national longitudinal study on unilateral CI re-
cipients; however, they did observe an association with a 
longer duration of hearing loss (i.e.,  ≥ 40 years) [UK Co-
chlear Implant Study Group, 2004]. In contrast, research-
ers reporting on a long-term comparative study involving 
a small group of unilateral CI recipients with several years 
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of CI experience observed a significant age effect and sug-
gested a possible influence of age-related comorbidities 
with increasing time [Damen et al., 2007].
 For future longitudinal studies, it may be of interest to 
collate more detailed information about changes in the 
severity of reported comorbidities, including tinnitus and 
dizziness, in general over time and to examine their as-
sociation with subjective outcomes.
 Longitudinal SSQ Outcomes 
 Results from repeated measures on the SSQ suggest 
significant improvement from preimplantation scores. 
The mean change from baseline (preimplantation status) 
to 1 year postimplantation ranged from 2.1 to 2.4 across 
SSQ subcategories and were notably well above the clini-
cally significant change reported by the developers of the 
SSQ, who suggest that a 1.0-scale-point difference is typ-
ical after providing a unilateral HA to hearing impaired 
adult groups [Noble and Gatehouse, 2004].
 An individual analysis of outcomes within our study 
group suggested that 70% of the individuals showed sig-
nificant improvement at 1 year postimplantation on one 
or more SSQ subcategories relative to baseline ratings. 
The proportion of subjects with a clinically significant 
change in SSQ scores increased to as high as 90% over 
time, while there were no subjects for any SSQ subcate-
gory who had a clinically meaningful decrease from base-
line to 3 years postimplantation. For some subjects, im-
provement in self-assessed ratings of hearing function 
continued beyond the first year postimplantation.
 As pointed out by researchers such as Mertens et al. 
[2015], auditory disability cannot be measured or reliably 
predicted based on laboratory testing of speech outcomes 
alone, but real-world measures such as questionnaires like 
the SSQ should be included to assess the preimplantation 
and posttreatment effects on hearing function over time.
 Predictors of SSQ Outcomes 
 In our study cohort, SSQ subcategory ratings were 
shown to differ between several covariate subgroups for 
the variables examined. As shown in  Table 5 , preimplan-
tation status, such as contralateral HA use, being younger 
than 65 years of age, implant side, and the ability to use 
the telephone, was associated with significantly higher 
scores on one or more of the SSQ subcategories at one or 
more of the assessment time points. In contrast, the re-
port of tinnitus at preimplantation had a significant neg-
ative effect for SSQ speech and SSQ qualities scores over 
time ( p = 0.002 and  p = 0.001, respectively).
 In a recent publication, examination of the outcomes 
on the SSQ for a group of nonimplanted hearing-impaired 
subjects versus normal-hearing subjects suggested that 
the main predictive effects of outcomes were in associa-
tion with hearing loss degree in the better ear and interau-
ral hearing loss asymmetry [Moulin and Richard, 2016]. 
As has also been asuggested by other researchers, closer 
examination of the degree of interaural asymmetry, in-
cluding the subsequent classification of the contralateral 
ear as either the better, the poorer or an equivalent hearing 
ear, may be relevant to further assess the impact on out-
comes on the SSQ [UK Cochlear Implant Study Group, 
2004; Noble and Gatehouse, 2006; Noble et al., 2008].
 Study Design Limitations 
 While this was an observational study, with investiga-
tors instructed to offer participation to consecutively im-
planted adult and adolescent Nucleus ® implant recipi-
ents treated in routine practice, the potential for enrol-
ment bias cannot be excluded. Investigator motivation 
and time to participate may vary and influence the ap-
proach towards newly implanted recipients for study par-
ticipation. Inherent self-selection bias by the recipient 
may also exist. For example, recipients willing to partici-
pate may be inherently more motivated, active, or posi-
tive in reporting their outcomes than those who decline 
to participate. It is also possible that the willingness and 
agreement to participate are influenced by the recipient’s 
levels of anxiety and or pain related to upcoming or recent 
surgical therapy. Furthermore, as the study design re-
quires reading skills to complete self-assessments of out-
comes, those unable to read are less likely to be enrolled. 
as are recipients with severe comorbidities.
 Hence, while attempts are made to reduce possible en-
rolment bias as much as possible, caution should be exer-
cised when attempting to generalize the findings of this 
study beyond the study cohort to the treatment popula-
tion at large, without further exploration of the population 
characteristics of the enrolled cohort versus the nonen-
rolled implant recipient group at each participating site.
 The observational study design used calls for a record 
of baseline evaluations between the day of the surgery and 
the first fitting, with a recall time reference of “4 weeks 
prior to implantation.” A potential bias of preimplanta-
tion status evaluation may occur as a result of the condi-
tion of the recipient during the postsurgery healing phase, 
with possible pain or discomfort and the absence of audi-
tory stimulation in the implanted ear. Furthermore, as 
some recipients may have been asked to assess their pre-
implantation status immediately before the first fitting of 
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their sound processor, this may have extended the recall 
period for the 4-week reference interval by up to 2 or 3 
months. Nonetheless, as the preimplantation reference 
interval is marked by a significant milestone, the implant 
surgery, the degree of recall bias, specifically in relation to 
health status, is expected to be minimized [Barsky, 2002].
 As the numbers of available data sets were reduced at 
each subsequent postimplantation interval, repeating the 
analysis of all available data for larger numbers of en-
rolled CI recipients may be of benefit to further examine 
changes in outcomes over time and the influencing fac-
tors.
 Conclusions 
 Our collaborative, multinational observational study 
of longitudinal patient-related outcomes for a cohort of 
routinely treated unilateral CI recipients evaluated via 
standardized self-assessment measures, i.e., the HUI3 
and SSQ, demonstrated significant improvements in 
health-related quality of life and real-life hearing function 
following implantation for the group.
 Mean improvements remained relatively stable be-
yond 1 year postimplantation for the available data sets at 
2 and 3 years postimplantation. In view of the multicul-
tural population, examination and consideration of dif-
ferences between countries for each outcome used are 
recommended, with adaptation of the longitudinal mod-
els used as appropriate. Changes in outcome measures 
were significantly associated with recipient characteris-
tics as possible predictors of performance over time. Spe-
cifically, associations with one or more outcome mea-
sures were noted for the following preimplantation vari-
ables: age at implantation, implantation side, telephone 
use, contralateral hearing aid use, and additional comor-
bidities.
 The subjective outcome measures used in our study 
design provide a holistic view of the real-life treatment 
benefits of routine CI therapy for adult recipients. Fur-
thermore the measures used may be feasible for routine 
clinical use and enable aggregation of cross-cultural data 
sets as medical evidence to support decisions by health 
professionals and service providers.
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